SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
344,580
301,034
154,584
5,421
1,253
Cost of Revenue
49,858
34,193
7,353
130
0
Gross Profit
294,722
266,841
147,231
5,291
1,253
Operating Expenses
Research Development
609,850
401,843
166,707
188,272
146,394
Selling General and Administrative
215,885
207,761
122,682
83,749
75,043
Total Operating Expenses
855,938
610,469
290,442
272,021
221,437
Operating Income or Loss
-561,216
-343,628
-143,211
-266,730
-220,184
Interest Expense
32,691
33,709
5,781
-
-
Total Other Income/Expenses Net
14,862
10,139
96,573
-2,548
0
Income Before Tax
-571,529
-362,610
-48,628
-267,265
-220,030
Income Tax Expense
-1,195
-692
2,060
-
-
Income from Continuing Operations
-570,334
-361,918
-50,688
-267,265
-220,030
Net Income
-570,334
-361,918
-50,688
-267,265
-220,030
Net Income available to common shareholders
-570,334
-361,918
-50,688
-267,265
-220,030
Reported EPS
Basic
-
-5.46
-0.86
-5.49
-5.20
Diluted
-
-5.46
-0.86
-5.49
-5.20
Weighted average shares outstanding
Basic
-
66,250
58,818
48,697
42,290
Diluted
-
66,250
58,818
48,697
42,290
EBITDA
-
-342,763
-142,158
-266,730
-220,184